Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Cybin Inc (CLXPF)

Cybin Inc (CLXPF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Psychedelics Could Positively Impact the $2.5 Trillion Mental Health Market

Psychedelics could soon revolutionize the $2.5 trillion mental health market. In fact, according to co-CEO of the ATMA Journey Centers, David Harder, a quoted in a company press release, “The surge...

CYBN : 0.4270 (+9.49%)
CLXPF : 3.0200 (-1.31%)
FTRP.TO : 1.09 (+5.83%)
FTRP : 4.2105 (+1.07%)
MCUR.CN : 0.075 (+36.36%)
MCURF : 0.0499 (+21.71%)
ATAI : 1.8450 (+3.65%)
NEON.CN : 0.010 (unch)
NMDBF : 0.0076 (+11.76%)
Psychedelics Could Alter a Potential $2.5 Trillion Mental Health Market

Psychedelics could soon revolutionize the $2.5 trillion mental health market. In fact, according to ...

CYBN : 0.4270 (+9.49%)
CLXPF : 3.0200 (-1.31%)
FTRP.TO : 1.09 (+5.83%)
FTRP : 4.2105 (+1.07%)
MCURF : 0.0499 (+21.71%)
ATAI : 1.8450 (+3.65%)
NMDBF : 0.0076 (+11.76%)
FTRP.CN : 5.550 (+1.46%)
MCUR.CN : 0.075 (+36.36%)
NEON.CN : 0.010 (unch)
Cybin to Commence Trading on the NYSE American on August 5

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that its common shares will open...

CYBN.NE : 0.5800 (+16.00%)
CLXPF : 3.0200 (-1.31%)
Cybin Receives Final Approval to Commence Trading on the NYSE American on or About August 5

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has received approval for...

CYBN.NE : 0.5800 (+16.00%)
CLXPF : 3.0200 (-1.31%)
Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Common Shares

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, announced today the pricing of its previously announced...

CYBN.NE : 0.5800 (+16.00%)
CYBN : 0.4270 (+9.49%)
CLXPF : 3.0200 (-1.31%)
Cybin Announces Conditional Listing Approval from NYSE American

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has received conditional...

CYBN.NE : 0.5800 (+16.00%)
CLXPF : 3.0200 (-1.31%)
Cybin Files its 13th Patent Application and Announces Digital Therapeutics Strategy

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed its 13th new provisional...

CYBN.NE : 0.5800 (+16.00%)
CLXPF : 3.0200 (-1.31%)
Cybin to Participate in Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit on July 13th

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive...

CYBN.NE : 0.5800 (+16.00%)
CLXPF : 3.0200 (-1.31%)
Cybin Expands to Europe and Provides Update on Intellectual Property Portfolio

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced the scaling up of its European operations...

CYBN.NE : 0.5800 (+16.00%)
CLXPF : 3.0200 (-1.31%)
Rising Prevalence of Mental Depression & Anxiety Major Drivers Propelling Demand In Psychedelic Drugs Market

Palm Beach, FL – July 7, 2021 – Psychedelic drugs and therapies are truly becoming mainstream and are expected to become even more so in the years to come. Psychedelic drugs involve various types of...

CYBN.NE : 0.5800 (+16.00%)
OPTI.CN : 0.2300 (-2.13%)
OPTHF : 0.1703 (-4.81%)
MNMD : 3.44 (+0.88%)
CMPS : 10.47 (+0.87%)
ATAI : 1.8450 (+3.65%)
CLXPF : 3.0200 (-1.31%)
CYBN : 0.4270 (+9.49%)
GTMS.TO : 3.00 (+3.45%)
GBNH : 2.14 (+5.42%)

Barchart Exclusives

2 Reasons Foot Locker Is a Retailer to Watch in 2023
Credit Suisse analyst Michael Binetti upgraded Foot Locker stock on Wednesday from Neutral to Outperform. More importantly, the analyst raised his target price by more than 60% to $62, 38% higher than where it’s currently trading.    Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar